- Trial phase
- Phase 1/2
- Time to market
- ARV-806 is in Phase 1 dose escalation with no internal Phase 2/3 plans; the company is seeking an out-licensing partner for further development. Even if partnered, approval would likely be many years away given the early stage and competitive landscape.
- Why 3/10
- ARV-806 has no confirmed hard dated binary catalyst in the next ~12 months. The Phase 1 data readout was previously guided for H2 2026 but was removed from the milestone schedule in the Q3 2026 earnings call (Nov 3, 2026). The company is seeking to out-license the asset, making any future catalyst dependent on a partner. ImpactScore is 3 because this is an early-stage, deprioritized asset at a company with multiple other programs including an approved product.
The next catalyst for ARV-806 is the Phase 1 monotherapy dose escalation data readout, which was previously guided for the second half of 2026 but was removed from the milestone schedule in the Q3 2026 earnings call (Nov 3, 2026). If data are released, positive results could attract a licensing partner; negative or underwhelming data would likely make out-licensing difficult and confirm the asset's diminished value within Arvinas. The stock already trades near its 52-week low, reflecting this de-prioritization.
Price Chart
Executive Summary
ARV-806 is an investigational PROTAC drug designed to degrade the mutant KRAS G12D protein, a common driver of pancreatic, colorectal, and lung cancers. It is in a Phase 1/2 first-in-human clinical trial (NCT07023731) that started in May 2025. However, Arvinas has significantly deprioritized this asset: it completed dose escalation enrollment but plans to out-license any further development. In the Q3 2026 earnings call (Nov 3, 2026), ARV-806 was removed from the corporate pipeline chart and milestone schedule, with management instead highlighting three other pipeline programs. Meanwhile, competitor Astellas has advanced its own KRAS G12D degrader (ASP3082/setidegrasib) into Phase 3 trials. ARVN stock dropped ~11.7% on Nov 5, 2026 to $6.55, near its 52-week low, reflecting market disappointment with the pipeline reprioritization.
How It Works
ARV-806 is a PROTAC (PROteolysis TArgeting Chimera) drug, a type of molecule that works like a garbage disposal for a specific cancer-causing protein. One end of the molecule grabs onto the mutant KRAS G12D protein (a common driver of pancreatic, colorectal, and lung cancers), while the other end recruits the cell's natural protein-disposal system (the proteasome). This forces the cell to tag and destroy the mutant KRAS protein, eliminating it entirely. Unlike traditional cancer drugs that simply block a protein's activity, PROTACs remove the protein itself.
Trial Status
The Phase 1/2 first-in-human study (NCT07023731) began May 29, 2025, targeting 76 patients across 14 sites. Dose escalation enrollment in Phase 1 was completed as of Q1 2026. The trial was last updated September 2026 and is estimated to complete by November 30, 2026. A trial-in-progress poster was presented at ASCO-GI 2026. Preclinical data presented at AACR-NCI-EORTC (Oct 2025) showed sub-nanomolar KRAS G12D degradation potency and >25-fold improved anti-proliferative activity versus inhibitors and another clinical degrader.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 monotherapy dose escalation data readout (previously guided for H2 2026, but removed from milestone schedule in Q3 2026 earnings)
- Potential out-licensing or partnership agreement for further ARV-806 development
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ARVINAS, INC. S-3 ARVN ·Originating report